EP1363638A4 - USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND / OR ANXIETIES AND USEFUL CONNECTIONS FOR SUCH PROCEDURES - Google Patents

USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND / OR ANXIETIES AND USEFUL CONNECTIONS FOR SUCH PROCEDURES

Info

Publication number
EP1363638A4
EP1363638A4 EP02714918A EP02714918A EP1363638A4 EP 1363638 A4 EP1363638 A4 EP 1363638A4 EP 02714918 A EP02714918 A EP 02714918A EP 02714918 A EP02714918 A EP 02714918A EP 1363638 A4 EP1363638 A4 EP 1363638A4
Authority
EP
European Patent Office
Prior art keywords
anxiety
depression
treatment
methods
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02714918A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1363638A2 (en
Inventor
Thomas P Blackburn
Michael Konkel
Lakmal W Boteju
Ian Jamie Talisman
John M Wetzel
Mathivanan Packiarajan
Heidi Chen
Hermo Jimenez
Bharat Lagu
Kitae Lim
Stewart Noble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to EP09010004A priority Critical patent/EP2140862A3/en
Priority to EP09010003A priority patent/EP2140864A3/en
Priority claimed from PCT/US2002/004608 external-priority patent/WO2002060392A2/en
Publication of EP1363638A2 publication Critical patent/EP1363638A2/en
Publication of EP1363638A4 publication Critical patent/EP1363638A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP02714918A 2001-01-31 2002-01-31 USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND / OR ANXIETIES AND USEFUL CONNECTIONS FOR SUCH PROCEDURES Withdrawn EP1363638A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09010004A EP2140862A3 (en) 2001-01-31 2002-01-31 Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
EP09010003A EP2140864A3 (en) 2001-01-31 2002-01-31 Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US775341 1991-10-15
US77534101A 2001-01-31 2001-01-31
PCT/US2002/004608 WO2002060392A2 (en) 2001-01-31 2002-01-31 Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP09010004A Division EP2140862A3 (en) 2001-01-31 2002-01-31 Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
EP09010003A Division EP2140864A3 (en) 2001-01-31 2002-01-31 Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods

Publications (2)

Publication Number Publication Date
EP1363638A2 EP1363638A2 (en) 2003-11-26
EP1363638A4 true EP1363638A4 (en) 2010-01-06

Family

ID=25104097

Family Applications (3)

Application Number Title Priority Date Filing Date
EP02714918A Withdrawn EP1363638A4 (en) 2001-01-31 2002-01-31 USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND / OR ANXIETIES AND USEFUL CONNECTIONS FOR SUCH PROCEDURES
EP09010004A Withdrawn EP2140862A3 (en) 2001-01-31 2002-01-31 Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
EP09010003A Withdrawn EP2140864A3 (en) 2001-01-31 2002-01-31 Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP09010004A Withdrawn EP2140862A3 (en) 2001-01-31 2002-01-31 Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
EP09010003A Withdrawn EP2140864A3 (en) 2001-01-31 2002-01-31 Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods

Country Status (22)

Country Link
EP (3) EP1363638A4 (cs)
JP (3) JP4739650B2 (cs)
KR (1) KR20040041092A (cs)
CN (2) CN100446767C (cs)
AU (2) AU2002247149B2 (cs)
BG (1) BG108114A (cs)
BR (1) BR0206844A (cs)
CA (3) CA2672805A1 (cs)
CZ (1) CZ20032341A3 (cs)
EA (1) EA006486B1 (cs)
HR (1) HRP20030608A2 (cs)
HU (1) HUP0401858A3 (cs)
IL (2) IL157102A0 (cs)
IS (1) IS6880A (cs)
MX (1) MXPA03006812A (cs)
NO (1) NO20033388L (cs)
NZ (1) NZ527163A (cs)
PL (1) PL369270A1 (cs)
SK (1) SK9562003A3 (cs)
UA (1) UA74421C2 (cs)
YU (1) YU60803A (cs)
ZA (1) ZA200305686B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363638A4 (en) * 2001-01-31 2010-01-06 Lundbeck & Co As H USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND / OR ANXIETIES AND USEFUL CONNECTIONS FOR SUCH PROCEDURES
PL372390A1 (en) * 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
CN101973925B (zh) * 2010-10-15 2012-03-28 中国药科大学 具有抗炎活性的2-吲哚酮类化合物、其制备方法及医药用途
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂
BR112019013571A2 (pt) * 2016-12-29 2020-01-07 Minoryx Therapeutics S.L. Compostos heteroarila e seu uso
CN111032039B (zh) 2017-08-03 2024-03-26 卡莱克汀科学有限责任公司 用于预防和治疗医学障碍的化合物及其用途
KR20210124308A (ko) * 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN113317221B (zh) * 2021-06-18 2023-01-31 青岛百宜电器有限公司 自动梳毛机

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50140441A (cs) * 1974-04-23 1975-11-11

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477349A (en) * 1975-09-24 1977-06-22 Ciba Geigy Ag Azo pigments
MA18829A1 (fr) * 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
US4946956A (en) * 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
JPH02300264A (ja) * 1989-05-16 1990-12-12 Fuji Photo Film Co Ltd アミノピリミジンアゾメチン色素とその製造方法
JPH02308248A (ja) * 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
HUT64323A (en) * 1992-06-09 1993-12-28 Richter Gedeon Vegyeszet Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives
DK69693D0 (da) * 1993-06-14 1993-06-14 Neurosearch As Farven lilla
ATE360617T1 (de) * 1994-06-15 2007-05-15 Otsuka Pharma Co Ltd Benzoheterocyclische verbindungen verwendbar als vasopressin- oder oxytocin-modulatoren
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DK0765858T3 (da) * 1995-04-12 2000-05-01 Ueno Seiyaku Oyo Kenkyujo Kk Naphtholderivater og fremgangsmåder til fremstilling af samme
KR100457502B1 (ko) * 1995-06-02 2005-09-05 사노피-신델라보 옥사졸리디논유도체,그것의제법및치료학적사용
WO1998055457A1 (en) * 1995-10-13 1998-12-10 Transitions Optical, Inc. Substituted naphthopyrans
FR2741072B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
DK0891978T3 (da) * 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
CN1240210A (zh) * 1998-04-17 2000-01-05 伊莱利利公司 取代的三环化合物
EP1083913A4 (en) * 1998-06-05 2004-03-17 Regent Court Technologies MONOAMINE OXIDASE (MAO) INHIBITORS AND THEIR USE.
PE20001236A1 (es) * 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
CH1196397H1 (de) * 1999-06-02 2007-05-31 Nps Pharma Inc Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
CA2396693A1 (en) * 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
EP1363638A4 (en) * 2001-01-31 2010-01-06 Lundbeck & Co As H USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND / OR ANXIETIES AND USEFUL CONNECTIONS FOR SUCH PROCEDURES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50140441A (cs) * 1974-04-23 1975-11-11

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
ABDEL-RAHMAN, R. M. ET AL: "Synthesis of some 1,2,4-triazino[4,3-a]indole derivatives", JOURNAL OF THE INDIAN CHEMICAL SOCIETY ( 1991 ), 68(11), 621-4 CODEN: JICSAH; ISSN: 0019-4522, 1991, XP008115404 *
BAIOCCHI L ET AL: "SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF SOME NEW INDOLOÄ2,1-BÜQUINAZOLIN-6(12H)ONES", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 48, no. 4, 1 January 1993 (1993-01-01), pages 487 - 501, XP009063144, ISSN: 0014-827X *
CURRENT SCIENCE , 51(23), 1100-3 CODEN: CUSCAM; ISSN: 0011-3891, 1982 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OTOMASU, HIROTAKA ET AL: "Spiro[indoline-3,2'-thiazolidine]-2,4'-diones", XP002557734, retrieved from STN Database accession no. 1976:432991 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SEN GUPTA, A. K. ET AL: "Synthesis of indole derivatives as potential biodynamic agents: Part II: 1,5-Disubstituted 3-(5-aryl-1,3,4-oxadiazol-2-yl)-iminoindolin-2-ones as possible antibacterial and CNS active agents", XP002557738, retrieved from STN Database accession no. 1983:83236 *
DATABASE REGISTRY 16 November 1984 (1984-11-16), XP002557735, retrieved from STN Database accession no. 59618-76-7 *
DATABASE REGISTRY 17 November 2000 (2000-11-17), XP002557739, retrieved from STN Database accession no. 303149-06-6 *
DATABASE REGISTRY 17 November 2000 (2000-11-17), XP002557741, retrieved from STN Database accession no. 303149-14-6 *
DATABASE REGISTRY 17 November 2000 (2000-11-17), XP002557742, retrieved from STN Database accession no. 303149-12-4 *
DATABASE REGISTRY 18 December 2000 (2000-12-18), XP002557736, retrieved from STN Database accession no. 309271-04-3 *
DATABASE REGISTRY 19 December 2000 (2000-12-19), XP002557737, retrieved from STN Database accession no. 309744-91-0 *
DATABASE REGISTRY 22 November 2000 (2000-11-22), XP002557740, retrieved from STN Database accession no. 303984-51-2 *
JOSHI, K. C. ET AL: "Possible psychopharmacological agents. X. Synthesis of some fluorine-containing indole-2,3-dione derivatives", JOURNAL FUER PRAKTISCHE CHEMIE (LEIPZIG) ( 1980 ), 322(2), 314-20 CODEN: JPCEAO; ISSN: 0021-8383, 1980, XP002557733 *
KNOTZ, FLORIAN: "Preparation of antiviral and antimicrobial substances. 2. Acyl hydrazones and thiosemicarbazones of 1-isatin acetic acid derivatives", SCIENTIA PHARMACEUTICA ( 1970 ), 38(3), 163-72 CODEN: SCPHA4; ISSN: 0036-8709, 1970, XP008115405 *
See also references of WO02060392A2 *
SEN GUPTA A K ET AL: "Synthesis of indole derivatives as potential biodynamic agents: Part II: 1,5-Disubstituted 3-(5-aryl-1,3,4-oxadiazol-2-yl)-iminoindolin-2 ones as possible antibacterial and CNS active agents", CURRENT SCIENCE, INDIAN ACADEMY OF SCIENCES, IN, vol. 51, no. 23, 5 December 1982 (1982-12-05), pages 1100 - 1103, XP008115354, ISSN: 0011-3891 *
VARMA, RAJENDRA S. ET AL: "Potential biologically active agents. Part XLIII. Synthesis of substituted 2-phenylbenzoxazoles as CNS active agents", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY ( 1985 ), 24B(3), 280-5 CODEN: IJSBDB; ISSN: 0376-4699, 1985, XP008115349 *
ZAM A ET AL: "Synthesis and pharmacological activities of Mannich bases using indole-2,3-dione/3-phenylimino-2-indolinone as amine moiety", JOURNAL OF THE INSTITUTION OF CHEMISTS (INDIA), CALCUTTA, IN, vol. 68, no. 4, 1 January 1996 (1996-01-01), pages 114 - 116, XP008115350, ISSN: 0020-3254 *

Also Published As

Publication number Publication date
BR0206844A (pt) 2005-07-12
YU60803A (sh) 2006-05-25
EP2140862A2 (en) 2010-01-06
NO20033388L (no) 2003-09-24
EP1363638A2 (en) 2003-11-26
IS6880A (is) 2003-07-21
JP2010006813A (ja) 2010-01-14
HRP20030608A2 (en) 2005-06-30
AU2008200385A1 (en) 2008-02-21
CN100446767C (zh) 2008-12-31
CA2672805A1 (en) 2002-08-08
SK9562003A3 (en) 2004-04-06
EP2140864A3 (en) 2010-01-27
NZ527163A (en) 2006-02-24
EA200300850A1 (ru) 2004-06-24
JP4739650B2 (ja) 2011-08-03
AU2002247149B2 (en) 2007-10-25
BG108114A (bg) 2005-03-31
ZA200305686B (en) 2004-10-25
PL369270A1 (en) 2005-04-18
EP2140864A2 (en) 2010-01-06
CN101406469B (zh) 2012-06-13
NO20033388D0 (no) 2003-07-29
CA2671776C (en) 2012-12-18
CA2438582C (en) 2012-06-26
CA2438582A1 (en) 2002-08-08
HUP0401858A3 (en) 2009-06-29
IL198759A (en) 2013-06-27
CZ20032341A3 (cs) 2004-12-15
CN1499970A (zh) 2004-05-26
AU2008200385B2 (en) 2010-09-09
JP2009173657A (ja) 2009-08-06
EA006486B1 (ru) 2005-12-29
CA2671776A1 (en) 2002-08-08
UA74421C2 (uk) 2005-12-15
JP2004529089A (ja) 2004-09-24
MXPA03006812A (es) 2004-10-15
CN101406469A (zh) 2009-04-15
EP2140862A3 (en) 2010-02-17
KR20040041092A (ko) 2004-05-13
HUP0401858A2 (hu) 2004-12-28
IL157102A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
TNSN04001A1 (fr) Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase.
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHOD OF USE
EP1624935A4 (en) ANTI-ADHESION COMPOUNDS AND USE METHOD THEREFOR
DZ3209A1 (fr) Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
AU2002213409A1 (en) Galphaqproetin variants and their use in the analysis and discovery of agonists and antagonists of chemosensory receptors
ATE313537T1 (de) Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden
EP1265913A4 (en) CHARACTERIZATION OF THE INTERACTION BETWEEN GRP94 AND A LIGAND, AND CLEANING, SCREENING AND THERAPEUTIC PROCEDURES RELATING TO IT
EP1722797A4 (en) ISOCHINOLINE DERIVATIVES AND METHOD FOR THE APPLICATION THEREOF
EP1401321A4 (en) BLOOD FLOW MONITOR FOR SHOCK AND REVIVAL
EP1361872A4 (en) NEW LYSOPHOSPHIC ACID RECEPTOR AGONISTS AND ANTAGONISTS
EP1534683A4 (en) CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHOD OF USE
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
EP1817055A4 (en) OVR110 ANTIBODY COMPOSITIONS AND USE PROCEDURES
EP1812012A4 (en) PROTEIN TYROSINE PHOSPHATASE INHIBITOR AND METHOD FOR THEIR USE
IL198759A (en) Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety
EP1412746A4 (en) HADHs AS P21 PATH MODIFICATORS AND USE METHOD
EP1633749A4 (en) Deazaflavin compounds and methods of use thereof
DE69915113D1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
EP1928496A4 (en) C / CLP ANTAGONISTS AND METHOD OF USE
EP1954312A4 (en) DETERMINATION OF SOLUBLE ADIPONECTIN RECEPTOR PEPTIDES AND USE FOR DIAGNOSIS AND TREATMENT
EP1461450A4 (en) T-BET COMPOSITIONS AND METHOD OF USE THEREOF
EP1598987A4 (en) METHOD AND DEVICE FOR DETERMINING THE USE CONDITION
EP1161451A4 (en) HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
FR2849182B1 (fr) Dispositif pour la mesure de l'epaisseur de couches minces

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030901

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NOBLE, STEWART

Inventor name: LIM, KITAE

Inventor name: LAGU, BHARAT

Inventor name: JIMENEZ, HERMO

Inventor name: CHEN, HEIDI

Inventor name: PACKIARAJAN, MATHIVANAN

Inventor name: WETZEL, JOHN M.

Inventor name: TALISMAN, IAN JAMIE

Inventor name: BOTEJU, LAKMAL W.

Inventor name: KONKEL, MICHAEL

Inventor name: BLACKBURN, THOMAS P.

RTI1 Title (correction)

Free format text: USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1061190

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: H. LUNDBECK A/S

A4 Supplementary search report drawn up and despatched

Effective date: 20091208

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/24 20060101ALI20091130BHEP

Ipc: C07D 417/12 20060101ALI20091130BHEP

Ipc: C07D 413/06 20060101ALI20091130BHEP

Ipc: C07D 413/04 20060101ALI20091130BHEP

Ipc: C07D 409/14 20060101ALI20091130BHEP

Ipc: C07D 409/12 20060101ALI20091130BHEP

Ipc: C07D 409/06 20060101ALI20091130BHEP

Ipc: C07D 409/04 20060101ALI20091130BHEP

Ipc: C07D 405/14 20060101ALI20091130BHEP

Ipc: C07D 405/12 20060101ALI20091130BHEP

Ipc: C07D 403/12 20060101ALI20091130BHEP

Ipc: C07D 403/04 20060101ALI20091130BHEP

Ipc: C07D 401/14 20060101ALI20091130BHEP

Ipc: C07D 401/12 20060101ALI20091130BHEP

Ipc: C07D 401/06 20060101ALI20091130BHEP

Ipc: C07D 401/04 20060101ALI20091130BHEP

Ipc: C07D 239/50 20060101ALI20091130BHEP

Ipc: C07D 209/40 20060101ALI20091130BHEP

Ipc: A61K 31/506 20060101ALI20091130BHEP

Ipc: A61K 31/407 20060101AFI20091130BHEP

17Q First examination report despatched

Effective date: 20100610

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1061190

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140715